



OxySure (OXYS) and Estill Medical Technologies Launch Ebola Intervention Kit

FRISCO, Texas, November 4, 2014, (MarketWired) – OxySure Systems, Inc. (OTCQB: OXYS) the medical device innovator of life-saving easy-to-use emergency oxygen solutions with its FDA-cleared “oxygen from powder” technology, along with Estill Medical Technologies, the creator of the FDA-cleared “Thermal Angel Blood and IV Fluid Infusion Warmer”, today announced the launch of an Ebola Intervention Kit.

OxySure’s “Ebola Intervention Kit” is designed to provide caregivers two critical tools for the early treatment of Ebola patients or for anyone showing possible Ebola symptoms. According to the Centers for Disease Control and Prevention (CDC), when someone is suspected of showing Ebola symptoms “the following basic interventions, when used early, can significantly improve the chances of survival:

- Providing intravenous (IV) fluids and balancing electrolytes (body salts)
- Maintaining oxygen status and blood pressure
- Treating other infections if they occur”

The “Ebola Intervention Kit” (Product reference number TA-OXYS-EIK) consists of the Thermal Angel Blood and IV Fluid Warmer and the OxySure 615 Portable Emergency Oxygen System. The companies are also in discussions with other suppliers to possibly expand the kit in a modular way.

For caregivers who wish to warm the IV fluids given to their patients, the “Ebola Intervention Kit” includes the U.S. Military’s Thermal Angel Ultra Operations Module, which provides a disposable Thermal Angel, an Ultra Battery 1, and all of the charging options for field use. The Thermal Angel allows the caregiver to warm the IV fluids given to the patient, in order to help prevent fluid-induced hypothermia into an already stressed patient.

For caregivers who wish to provide emergency oxygen to their patients, the “Ebola Intervention Kit” includes the OxySure 615 Portable Oxygen System, which creates oxygen from powder, requiring no oxygen tanks or power and can be used in remote, undeveloped or rural situations.

By combining the Thermal Angel fluid warmer and the OxySure emergency oxygen solution, caregivers now have access to a kit that requires no AC power and is portable, includes disposables that can be discarded, and is easy to use with simple instructions.

In a joint statement, Julian Ross, CEO and Jay Lopez, President stated: “With the Ebola issue, we are very aware of the challenges that caregivers face in supporting their patients. We believe that our new Ebola Intervention Kit will be especially beneficial to those caregivers who are challenged with supporting patients in areas that lack power, or need to have the ability to easily dispose of products that are used to treat Ebola patients. We have seen great success in

supporting the U.S. Military with our Thermal Angel Blood and IV Fluid Warmer, so this is another example of the military leading the way to changes in civilian medicine.”

For additional information about the Ebola Intervention Kit:

<http://www.thermalangel.com/products/kits/ebola-intervention-kit-ta-oxys-eik/>

For additional information regarding the Thermal Angel Fluid Warmer:

<http://www.thermalangel.com/products/thermal-angel-ta-200/>

For additional information regarding the OxySure emergency oxygen device:

<http://www.oxysure.com/aed/index.php/new-model>

About OxySure Systems, Inc.

OxySure Systems, Inc. (OXYs) is a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions. The company pioneered a safe and easy to use solution to produce medically pure (USP) oxygen from inert powders. The company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems. OxySure's products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other "Immediately Dangerous to Life or Health" (IDLH) environments. www.OxySure.com

About Estill Medical, Inc.

Estill Medical Technologies, Inc. developed, markets and sells the Thermal Angel blood and intravenous fluid infusion warmer. The Thermal Angel is an FDA-cleared, battery powered, disposable, lightweight and portable device that is used to warm blood or IV fluid at the point of injury or stationary environments. The Thermal Angel fills the void in pre-hospital, hospital, EMS, Air Ambulance, military and government settings when an easy to use solution is required to infuse warmed fluids into a patient. The Thermal Angel combines the required features of a sterile fluid path with the intelligence of an advanced medical instrument creating a small, lightweight, disposable and portable fluid warmer that can follow a patient through the continuum of care. The Thermal Angel is the leading product procured by the U.S. Military. Estill holds three patents for the Thermal Angel in the U.S. as well as patents in other countries. For more information, please visit www.thermalangel.com.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts,

including, without limitation, statements that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development, may be deemed to be forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import also identify forward-looking statements. These statements are subject to risks and uncertainties. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Except as may be required under applicable law, we assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of OxySure Systems, Inc. can be found in the filings of OxySure Systems, Inc. with the U.S. Securities and Exchange Commission.

Investor Contacts:

Redchip Companies, Inc.

Jon Cunningham: jon@redchip.com

800-733-2447, ext. 107

www.redchip.com/

Stonegate Securities, Inc.

investors@oxysure.com

214-987-4121 / 972-294-6461

<http://www.stonegateinc.com/>